Health & WellnessS


Eye 1

Merck asks FDA for emergency approval of new COVID drug despite safety concerns

Tyler Durden
Zero Hedge
Mon, 11 Oct 2021 20:13 UTC
MERCK virus
© MERCK/Britannica.com/KJN
Despite warnings from scientists that its new COVID drug could have seriously harmful side effects like causing cancers and birth defects, Merck officially submitted the drug, Molnupiravir, to the FDA for approval. If it's approved, it would be the first antiviral pill to treat the virus.

According to the NYT, the drug would revolutionize COVID treatment since it would be able to relatively inexpensively treat many more high-risk patients sick with COVID, especially those that haven't been vaccinated (the drug was only tested on patients who hadn't been vaccinated). Still, the drug will be a cash cow for Merck, since Merck is planning to charge customers 40x the cost to make the drug.

Despite the price, countries are lining up for deals with Merck even before the drug has been approved. Merck has struck deals with the US government, as well as South Korea, Singapore, Malaysia, Australia and others.

The $700 course of the pill is meant to be taken at home as four capsules twice a day for five days, constituting a total of 40 pills. Per the trial data released by Merck - which was greeted with fawning from doctors and scientists - it halved hospitalizations and deaths (though the trial was cut short by a supervisory board who claimed the data was so positive it would be unethical to withhold the drug from the placebo group). The approval could come within weeks, per the NYT.

Comment: See also: Ivermectin is safer, and just as effective - probably more.

Read More...
Bullseye

Making the case: A natural immunity cheat sheet

Justin Hart
Rational Ground
Sun, 10 Oct 2021 17:09 UTC
covid vaccine protest
There's a lot we don't know about the current state of the pandemic. What we can say for almost certain now is that if you had Covid and recovered your immune system has all the tools it needs to combat the disease going forward. Marty Makary from Johns Hopkins University put it this way:

"During every month of this pandemic, I've had debates with other public researchers about the effectiveness and durability of natural immunity," he wrote in an Op-Ed for U.S. News & World Report in August.
"I've been told that natural immunity could fall off a cliff, rendering people susceptible to infection. But here we are now, over a year and a half into the clinical experience of observing patients who were infected, and natural immunity is effective and going strong, and that's because with natural immunity, the body develops antibodies to the entire surface of the virus, not just a spike protein constructed from a vaccine."
Read More...
Syringe

Steve Kirsch: 'At least 200,000 people have died from the Covid jabs in the US'

Dr. Joseph Mercola
Mercola.com
Sat, 09 Oct 2021 00:01 UTC
american vaccinated
Yesterday, October 8, 2021, I published a Highwire exclusive interview with Deborah Conrad, a physician's assistant who is blowing the whistle on COVID jab injuries, and the fact that these injuries are rarely reported because of a faulty VAERS database design.

Today you're in for yet another bombshell video: "Vaccine Secrets: COVID Crisis." It's the first episode of "The False Narrative Takedown Series," produced by Steve Kirsch, executive director of the COVID-19 Early Treatment Fund.

"Vaccine Secrets" complements and supports everything Conrad shared in her interview, so I highly recommend saving these files on your computer and watching both of them. Both are available on Bitchute.

Comment: 200K strikes us as too high a guesstimate. There could well be that many deaths-by-Covid-vaxx globally, but for the US alone it's probably more like 20K.

See also:

Read More...
Syringe

VAERS data show COVID vaccine serious injury close to 112,000, Pfizer asks FDA for approval to inject kids 5 to 11

Megan Redshaw
Children's Health Defense
Fri, 08 Oct 2021 06:51 UTC
Covid vaccine
VAERS data released Friday by the CDC included a total of 778,685 reports of adverse events from all age groups following COVID vaccines, including 16,310 deaths and 111,921 serious injuries between Dec. 14, 2020 and Oct. 1, 2021.
Read More...
Red Pill

Ivermectin: Truth & totalitarianism - Calling out the lie

Justus R. Hope, MD
The Desert Review
Mon, 04 Oct 2021 20:40 UTC
ivermectine
"Merck stock surged 10% Friday after it said its investigational pill cuts the risk of hospitalization and death in COVID-19 patients...The pill reduced the risk of hospitalization or death by about 50%," Merck and its partner, Ridgeback Biotherapeutics, said in a statement Friday.

"This is a phenomenal result. This is a profound game-changer to have an oral pill that had this kind of effect, this magnitude of effect in patients who are at high risk who are already symptomatic," former FDA Commissioner Scott Gottlieb said Friday on CNBC about results of the interim analysis.
"Meanwhile, shares of COVID vaccine makers Pfizer and Moderna fell 2.5% and 10%, respectively."
This puts Dr. Scott Gottlieb between a rock and a hard place. On the one hand, as a member of Pfizer's Board of Directors, he is paid handsomely to attend a few board meetings per year, yet on the other hand, he must not be too glowing in his praise of the antiviral, which might lead people away from the Pfizer vaccine. Moreover, it could affect sales just as it has already dropped the stock price.

In 2020, Gottlieb was paid $338,587 by Pfizer. In 2020, he also earned $525,850 as a director of Illumina. Due to his former FDA Chief status, Gottlieb is in high demand as one word of favor from him can send a stock price soaring.

He has served on multiple other boards, including Tempus Labs, National Resilience, and the Mount Sinai Health System. It must be a daunting task to walk the line by promoting one corporate interest while not offending any of the others.
Read More...
Attention

"Proceed with caution at your own peril' Merck's COVID 'super drug' poses serious health risks, scientists warn

Tyler Durden
Zero Hedge
Fri, 08 Oct 2021 09:56 UTC
molnupiravir
© UnknownCOVID drug molnupiravir
As it turns out, all the scientists and doctors who insisted that Merck's "revolutionary" COVID drug molnupiravir is extremely safe weren't faithfully adhering to "the science" after all. Because according to a report published Thursday by Barron's, some scientists are worried that the drug - which purportedly cut hospitalizations in half during a study that was cut short - could cause cancer or birth defects.

So much for having a "strong safety profile," as Dr. Scott Gottlieb claimed in an interview on the day Merck first publicized the research.

It's perfectly understandable why Merck might choose to play down this safety risk: assuming it's approved, the drug is widely expected to be one of "the most lucrative drugs ever" - which is one reason why Merck's shares soared into double-digit territory after the announcement.

As we reported earlier this week, Merck and its "partner" Ridgeback Biotherapeutics will profit immensely by charging customers up to 40x what it costs to make the drug, which Ridgeback originally licensed from Emory University for an "undisclosed sum". The drug was developed with funding from the federal government.

According to Barron's, some scientists who have studied the drug believe that its method of suppressing the virus could potentially run amok within the body.

Comment: This is just one more quick fix money-maker where-in profits would cover/cover-up any potential lawsuits.

Read More...
Magnify

Covid-19 infection may prompt Guillain-Barré syndrome, J&J vaccine implicated in increased risk

Zakiyah Ebrahim
News 24
Fri, 08 Oct 2021 09:27 UTC
coronavirus
© UC San FranciscoAn electron microscopy image of a cell infected by the coronavirus that causes COVID-19.
What are breakthrough infections?

Covid-19 infection may occasionally trigger Guillain-Barré syndrome, a rare but potentially serious neurological condition, according to new research appearing in the journal Brain, and published by Oxford University Press.

Guillain-Barré syndrome is an autoimmune neurological disorder where the body's immune system begins to attack the body itself and damage nerve cells. It can cause muscle weakness and occasionally paralysis.

Comment: Coronavirus itself has been found to have a very unusual make up, which, along with its other unusual effects on the body, including an increased risk of delirium, has led numerous researchers to conclude that it was engineered in a laboratory:

Read More...
Whistle

Top trans doctors blowing the whistle on 'sloppy' care

Abigail Shrier
bariweiss.substack.com
Mon, 04 Oct 2021 17:55 UTC
transgender surgery
© Glenn Asakawa/The Denver Post via Getty ImagesDr. Marci Bowers performs gender reassignment surgery in Trinadad’s Mount San Rafael Hospital.
In exclusive interviews, two prominent providers sound off on puberty blockers, 'affirmative' care, the inhibition of sexual pleasure, and the suppression of dissent in their field.

For nearly a decade, the vanguard of the transgender-rights movement — doctors, activists, celebrities and transgender influencers — has defined the boundaries of the new orthodoxy surrounding transgender medical care: What's true, what's false, which questions can and cannot be asked.

They said it was perfectly safe to give children as young as nine puberty blockers and insisted that the effects of those blockers were "fully reversible." They said that it was the job of medical professionals to help minors to transition. They said it was not their job to question the wisdom of transitioning, and that anyone who did — including parents — was probably transphobic. They said that any worries about a social contagion among teen girls was nonsense. And they never said anything about the distinct possibility that blocking puberty, coupled with cross-sex hormones, could inhibit a normal sex life.

Comment: Detrans woman regrets mastectomy: 'Don't indulge young people who think they're trans - many are mentally ill'

Read More...
Stock Down

Immunity weakens faster in men than women within months of Pfizer's second shot, study finds

Alisa Odenheimer and Robert Langreth
Calgary Herald
Thu, 07 Oct 2021 18:24 UTC
Pfizer vaccine
© ANDREJ IVANOV / BloombergA cyclist receives a dose of the Pfizer-BioNTech COVID-19 vaccine at the Gilles Villeneuve racetrack in Montreal, on Saturday, May 29, 2021.
Immunity provided by the COVID-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.

Protective antibodies decreased continuously during the six months after the administration of the second dose of the vaccine, according to a study of about 5,000 Israeli health workers, published Wednesday in the New England Journal of Medicine. The levels fell first at a sharp pace and later at a more moderate one.

Researchers worldwide are trying to identify the critical threshold of antibodies needed to prevent coronavirus infection, severe illness and death, said Gili Regev-Yochay, one of the authors of the study. Such studies will help assess risk levels for various groups and the measures needed to protect them, the researcher said.

Antibody levels were found to be lower in older people than in younger, and in immunosuppressed individuals compared to the healthy population, according to the study from Sheba Medical Center in Ramat Gan. Men's antibody counts were lower than those of women both at their peak and at the end of the study.
Read More...
Syringe

Study shows COVID vaccine does NOT reduce infection as countries with higher vaccination have more cases

David Heller
America's Frontline Doctors
Wed, 06 Oct 2021 11:52 UTC
VacciNation
In a comparison of 68 countries and 2,947 counties in the U.S., a new study concludes that jurisdictions with high vaccination rates do not have lower infection rates. A recent study just published in the European Journal of Epidemiology demonstrated that vaccination rates did not have an effect on new cases of COVID in the first week of September.
Read More...